Definitive Healthcare Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Definitive Healthcare Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $252.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $251.42M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $60.60M | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | $57.38M | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $54.55M | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $50.12M | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | $46.31M | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | $43.08M | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $39.82M | Aug 14, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $197.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $203.93M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $50.80M | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | $47.66M | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $42.77M | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $38.80M | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | $35.42M | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | $32.60M | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $29.95M | Aug 14, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($138.93M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($413.12M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($202.39M) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $9.87M | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | ($3.02M) | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | ($5.49M) | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | ($8.58M) | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | ($9.86M) | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | ($7.98M) | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $0 | Aug 14, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($224.27M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($710.82M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($329.80M) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | ($10.54M) | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | ($10.06M) | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | ($11.88M) | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | ($11.57M) | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | ($13.10M) | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | ($4.64M) | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | ($6.95M) | Aug 14, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $36.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.44M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $10.13M | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | $9.21M | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $8.71M | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $6.85M | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | $5.75M | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | $4.75M | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $4.28M | Aug 14, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $58.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $41.19M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $35.58M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $25.21M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $23.22M | Aug 14, 2023 |
| FY2021 | Dec 31, 2019 | ($7.13M) | Mar 15, 2022 |
| FY2021 | Jul 15, 2019 | $28.73M | Mar 15, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.34M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.98M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.33M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $6.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | Aug 14, 2023 |
| FY2021 | Dec 31, 2019 | $1.17M | Mar 15, 2022 |
| FY2021 | Jul 15, 2019 | $729.0K | Mar 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $735.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.83B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.12B | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | $2.12B | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $2.12B | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $2.14B | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | $2.12B | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | $1.87B | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $1.73B | Aug 14, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $482.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $626.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $640.68M | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | $648.31M | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $639.73M | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $649.50M | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | $617.78M | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | $591.46M | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $560.08M | Aug 14, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $393.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.08B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.32B | Feb 27, 2025 |
| FY2022 | Sep 30, 2022 | $1.32B | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | $1.32B | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | $1.33B | Aug 14, 2023 |
| FY2023 | Dec 31, 2021 | $1.26B | Feb 28, 2024 |
| FY2022 | Sep 30, 2021 | $1.26B | Aug 14, 2023 |
| FY2022 | Jun 30, 2021 | $1.26B | Aug 14, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($779.51M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($640.57M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($227.45M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($25.06M) | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | ($34.93M) | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | ($31.91M) | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | ($26.42M) | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | ($17.84M) | Aug 14, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $105.38M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $130.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $146.93M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $387.50M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $24.77M | Mar 15, 2022 |
| FY2021 | Dec 31, 2019 | $8.62M | Mar 15, 2022 |
| FY2021 | Jul 15, 2019 | $17.06M | Mar 15, 2022 |
| FY2021 | Dec 31, 2018 | $19.36M | Mar 15, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $244.06M | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $257.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2022 | $266.41M | Aug 14, 2023 |
| FY2021 | Dec 31, 2021 | $273.28M | Mar 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Aug 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Aug 14, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Aug 14, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Aug 14, 2023 |